{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:50:11Z","timestamp":1773683411775,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The interaction between cancer vaccine adjuvants and myeloid-derived suppressor cells (MDSCs) is currently poorly understood. Very small size proteoliposomes (VSSP) are a nanoparticulated adjuvant under investigation in clinical trials in patients with renal carcinoma, breast cancer, prostate cancer, and cervical intraepithelial neoplasia grade III. We found that VSSP adjuvant induced a significant splenomegaly due to accumulation of CD11b+Gr-1+ cells. However, VSSP-derived MDSCs showed a reduced capacity to suppress both allogeneic and Ag-specific CTL response compared with that of tumor-induced MDSCs. Moreover, splenic MDSCs isolated from tumor-bearing mice treated with VSSP were phenotypically more similar to those isolated from VSSP-treated tumor-free mice and much less suppressive than tumor-induced MDSCs, both in vitro and in vivo. Furthermore, different from dendritic cell vaccination, inoculation of VSSP-based vaccine in EG.7-OVA tumor-bearing mice was sufficient to avoid tumor-induced tolerance and stimulate an immune response against OVA Ag, similar to that observed in tumor-free mice. This effect correlated with an accelerated differentiation of MDSCs into mature APCs that was promoted by VSSP. VSSP used as a cancer vaccine adjuvant might thus improve antitumor efficacy not only by stimulating a potent immune response against tumor Ags but also by reducing tumor-induced immunosuppression.<\/jats:p>","DOI":"10.4049\/jimmunol.1001465","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T06:27:28Z","timestamp":1291703248000},"page":"264-274","source":"Crossref","is-referenced-by-count":47,"title":["Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant"],"prefix":"10.1093","volume":"186","author":[{"given":"Audry","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Center of Molecular Immunology , Havana 11600 ,","place":["Cuba"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Circe","family":"Mesa","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology , Havana 11600 ,","place":["Cuba"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Marigo","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico , 35128 Padua"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Dolcetti","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico , 35128 Padua"},{"name":"Venetian Institute for Molecular Medicine , 35129 Padua ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Clavell","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology , Havana 11600 ,","place":["Cuba"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Oliver","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology , Havana 11600 ,","place":["Cuba"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Center of Molecular Immunology , Havana 11600 ,","place":["Cuba"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Bronte","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico , 35128 Padua"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"2025032410561096500_r1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(04)01610-9","article-title":"Part I: vaccines for solid tumours","volume":"5","author":"Mocellin","year":"2004","journal-title":"Lancet Oncol."},{"key":"2025032410561096500_r2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coi.2004.01.003","article-title":"Animal models of tumor immunity, immunotherapy and cancer vaccines","volume":"16","author":"Ostrand-Rosenberg","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"2025032410561096500_r3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00008390-200106000-00003","article-title":"A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo","volume":"11","author":"Carr","year":"2001","journal-title":"Melanoma Res."},{"key":"2025032410561096500_r4","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-06-1075","article-title":"Complete antitumor protection by perioperative immunization with GM3\/VSSP vaccine in a preclinical mouse melanoma model","volume":"12","author":"Gabri","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2025032410561096500_r5","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res."},{"key":"2025032410561096500_r6","first-page":"7563","article-title":"Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma","volume":"61","author":"Tatsumi","year":"2001","journal-title":"Cancer Res."},{"key":"2025032410561096500_r7","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/sj.bjc.6604266","article-title":"Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings","volume":"98","author":"Jonasch","year":"2008","journal-title":"Br. J. Cancer"},{"key":"2025032410561096500_r8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"2025032410561096500_r9","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2025032410561096500_r10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"2025032410561096500_r11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00262-004-0577-x","article-title":"Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?","volume":"53","author":"Malmberg","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"2025032410561096500_r12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1172\/JCI31422","article-title":"Altered macrophage differentiation and immune dysfunction in tumor development","volume":"117","author":"Sica","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2025032410561096500_r13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","article-title":"Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response","volume":"179","author":"Sinha","year":"2007","journal-title":"J. Immunol."},{"key":"2025032410561096500_r14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"2025032410561096500_r15","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1172\/JCI28828","article-title":"Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells","volume":"116","author":"Gallina","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2025032410561096500_r16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res."},{"key":"2025032410561096500_r17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat. Med."},{"key":"2025032410561096500_r18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00262-003-0443-2","article-title":"Derangement of immune responses by myeloid suppressor cells","volume":"53","author":"Serafini","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"2025032410561096500_r19","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood-2006-09-046201","article-title":"Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host","volume":"109","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"2025032410561096500_r20","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2025032410561096500_r21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"2025032410561096500_r22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"2025032410561096500_r23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0264-410X(99)00219-4","article-title":"Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP)","volume":"18","author":"Estevez","year":"1999","journal-title":"Vaccine"},{"key":"2025032410561096500_r24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2003.02.124","article-title":"Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine","volume":"21","author":"Carr","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"2025032410561096500_r25","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.22085","article-title":"Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant","volume":"119","author":"Ram\u00edrez","year":"2006","journal-title":"Int. J. Cancer"},{"key":"2025032410561096500_r26","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.vaccine.2005.07.049","article-title":"Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors","volume":"23","author":"Torr\u00e9ns","year":"2005","journal-title":"Vaccine"},{"key":"2025032410561096500_r27","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.vaccine.2005.08.111","article-title":"Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens","volume":"24","author":"Mesa","year":"2006","journal-title":"Vaccine"},{"key":"2025032410561096500_r28","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.vaccine.2004.02.010","article-title":"Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation","volume":"22","author":"Mesa","year":"2004","journal-title":"Vaccine"},{"key":"2025032410561096500_r29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4049\/jimmunol.170.1.270","article-title":"IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice","volume":"170","author":"Bronte","year":"2003","journal-title":"J. Immunol."},{"key":"2025032410561096500_r30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"2025032410561096500_r31","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.4049\/jimmunol.175.7.4583","article-title":"Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells","volume":"175","author":"Kusmartsev","year":"2005","journal-title":"J. Immunol."},{"key":"2025032410561096500_r32","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.4049\/jimmunol.162.10.5728","article-title":"Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation","volume":"162","author":"Bronte","year":"1999","journal-title":"J. Immunol."},{"key":"2025032410561096500_r33","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.174.8.4880","article-title":"STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion","volume":"174","author":"Kusmartsev","year":"2005","journal-title":"J. Immunol."},{"key":"2025032410561096500_r34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/eji.200939903","article-title":"Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF","volume":"40","author":"Dolcetti","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"2025032410561096500_r35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxh025","article-title":"Polyriboinosinic polyribocytidylic acid [poly(I:C)]\/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes","volume":"16","author":"Fujimoto","year":"2004","journal-title":"Int. Immunol."},{"key":"2025032410561096500_r36","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.4049\/jimmunol.181.11.7670","article-title":"Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha\/beta","volume":"181","author":"Ngoi","year":"2008","journal-title":"J. Immunol."},{"key":"2025032410561096500_r37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1084\/jem.184.4.1413","article-title":"Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo","volume":"184","author":"De Smedt","year":"1996","journal-title":"J. Exp. Med."},{"key":"2025032410561096500_r38","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.161.4.1947","article-title":"Type I IFNs enhance the terminal differentiation of dendritic cells","volume":"161","author":"Luft","year":"1998","journal-title":"J. Immunol."},{"key":"2025032410561096500_r39","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/eji.200838645","article-title":"CD11c: not merely a murine DC marker, but also a useful vaccination target","volume":"38","author":"Kurts","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"2025032410561096500_r40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/annonc\/mdl158","article-title":"Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients","volume":"18","author":"Parmiani","year":"2007","journal-title":"Ann. Oncol."},{"key":"2025032410561096500_r41","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","article-title":"High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells","volume":"64","author":"Serafini","year":"2004","journal-title":"Cancer Res."},{"key":"2025032410561096500_r42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J. Immunol."},{"key":"2025032410561096500_r43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/PPO.0b013e3181eb3358","article-title":"Myeloid-derived suppressor cells in human cancer","volume":"16","author":"Nagaraj","year":"2010","journal-title":"Cancer J."},{"key":"2025032410561096500_r44","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion","volume":"65","author":"Zea","year":"2005","journal-title":"Cancer Res."},{"key":"2025032410561096500_r45","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.4049\/jimmunol.174.10.6095","article-title":"Reactive oxygen species and 12\/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection","volume":"174","author":"Brys","year":"2005","journal-title":"J. Immunol."},{"key":"2025032410561096500_r46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/intimm\/dxf076","article-title":"Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+ )immature myeloid suppressor cells","volume":"14","author":"Go\u00f1i","year":"2002","journal-title":"Int. Immunol."},{"key":"2025032410561096500_r47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0300-9084(03)00006-3","article-title":"Role of tumor-associated gangliosides in cancer progression","volume":"85","author":"Birkl\u00e9","year":"2003","journal-title":"Biochimie"},{"key":"2025032410561096500_r48","first-page":"363","article-title":"Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function","volume":"61","author":"Shurin","year":"2001","journal-title":"Cancer Res."},{"key":"2025032410561096500_r49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan","year":"2001","journal-title":"Nat. Immunol."},{"key":"2025032410561096500_r50","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"2025032410561096500_r51","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.4049\/jimmunol.179.8.5228","article-title":"CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis","volume":"179","author":"Zhu","year":"2007","journal-title":"J. Immunol."},{"key":"2025032410561096500_r52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1189\/jlb.0103010","article-title":"Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species","volume":"74","author":"Kusmartsev","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"2025032410561096500_r53","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1073\/pnas.0409783102","article-title":"Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination","volume":"102","author":"De Santo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032410561096500_r54","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J. Exp. Med."},{"key":"2025032410561096500_r55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbmt.2008.06.018","article-title":"CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy","volume":"14","author":"Morecki","year":"2008","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/1\/264\/62470950\/1001465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/1\/264\/62470950\/1001465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:42:58Z","timestamp":1743147778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/186\/1\/264\/8002909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1001465","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,1]]},"published":{"date-parts":[[2011,1,1]]}}}